Navigation Links
Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
Date:10/5/2010

NEW YORK, Oct. 5 /PRNewswire/ -- Regenicin™, Inc. (OTC Bulletin Board: WDST) (www.Regenicin.com), a clinical-stage biotechnology company, announced today that Mr. Christopher A. Hadsall, whose primary responsibilities will be to oversee government affairs, has agreed to join the company as Chief Operating Officer.  Mr. Hadsall brings 12 years of operational management expertise to Regenicin™ and will be instrumental in working with various military groups to build the company's distribution platform for the future commercialization of PermaDerm™, its proprietary tissue-engineered skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

Commenting on the announcement, Randall McCoy, Chief Executive Officer of Regenicin™ stated, "We are extremely pleased to have Chris join our management team.  His strong operational background, along with his proven ability to make a meaningful impact within large care organizations, make him the perfect choice. I look forward to working together with Chris as we build the foundation for Regenicin™'s promising future."

Mr. Hadsall most recently held several key managerial positions with Able Body Labor, a staffing solutions company serving their customers from over 170 branches in 25 states and putting more than 125,000 people to work each year.  From 2006 to 2010, Mr. Hadsall was the Regional Manager of Able Body's Westward Ho II subsidiary expansion program where he was responsible for the regional P&L as well as the creation and implementation of a multi-million dollar expansion plan.  Under his leadership the region's revenue generation for the company increased five-fold.  Prior to heading up that regional expansion, Mr. Hadsa
'/>"/>

SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
2. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
3. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
4. RF Technologies® Names Mark Harwood New President
5. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
6. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
7. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
8. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
9. Signum Biosciences Names Braham Shroot as Chief Executive Officer
10. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
11. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... and Proteomics Analytical Instruments Market 2014-2018" report to ... Genomics is the study of the gene ... the structure and functions of proteomes or sets of ... technology. Genomics involves the mapping of genes and DNA ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , ... meeting of shareholders will take place on June 4, ... Grand Vancouver, 403 Robson Street, Vancouver, BC V6B 6L9. ... of and vote at the meeting will be April ...
... be invested in the first phase of this personalized ... National Functional Genomics Center , funded ... by the U.S. Army Medical Research & ... Telemedicine & Advanced Technology Research Center (TATRC), ...
... SILVER SPRING, Md., April 24 United Therapeutics Corporation ... will release its 2009 first quarter financial results before ... host a half-hour teleconference on Friday, May 1, 2009, ... accessible by dialing 877-718-5092, with international callers dialing 719-325-4795. ...
Cached Biology Technology:NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer 2NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer 3
(Date:7/25/2014)... Boston, MA A study published online in the ... describes a novel approach to preventing cervical cancer based ... cervical cancer after removal of a discrete population of ... from a study that looked at squamocolumnar junction cells, ... canal and have been implicated as the origins of ...
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... use of a molecular testing panel developed at ... correct initial surgery for patients with thyroid nodules ... Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter., ... Center and other diagnostic testing agencies, improved the ... by 30 percent, according to the study published ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... A major international study with leadership from Massachusetts General ... associated with blood sugar or insulin levels. Two ... associated with glucose levels were also found to increase ... a related study from members of the same research ...
... a team of researchers is releasing data today that it ... the family of parasites that causes a deadly trio of ... nations for centuries. In an article to be published ... , Vanderbilt University scientist Galina Lepesheva and her team are ...
... A breakthrough discovery by scientists at the University of Kentucky ... diseases of the brain, spinal cord and the eye. ... visual science in the UK College of Medicine, found that ... proteins vimentin and glial fibrillary acidic protein (GFAP) ...
Cached Biology News:New gene variants associated with glucose, insulin levels, some with diabetes risk 2Scientists hope to end sleeping sickness by making parasite that causes it self-destruct 2Scientists hope to end sleeping sickness by making parasite that causes it self-destruct 3Kentucky study advances new target for CNS drug development 2
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Template and primers for preparation of internal control spots...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
...
Biology Products: